RBC Capital Maintains Outperform on Biogen, Raises Price Target to $379
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Biogen (NASDAQ:BIIB) and raised the price target from $341 to $379.
July 26, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's price target has been raised from $341 to $379 by RBC Capital, which maintains an 'Outperform' rating on the stock.
The raised price target and maintained 'Outperform' rating by RBC Capital indicates a positive outlook for Biogen. This could potentially lead to an increase in the stock's price in the short term as it signals confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100